Oncology Institute (TOI) major holder buys 125,000 shares

Rhea-AI Filing Summary

Oncology Institute, Inc. major shareholder Jorey Chernett reported an open-market purchase of 125,000 shares of common stock at a weighted average price of $3.11 per share. After this buy, Chernett directly owns 10,401,929 common shares. The purchase was executed in multiple trades between $3.04 and $3.15 per share.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chernett Jorey

(Last) (First) (Middle)

6222 INDIANWOOD TR.

(Street)

BLOOMFIELD HILLS MICHIGAN 48301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/24/2026		P		125,000	A	$3.11(1)	10,401,929	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.04 to $3.15, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased.

	/s/ Jorey Chernett	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Jorey Chernett report in the latest Form 4 for TOI?

Jorey Chernett reported buying 125,000 shares of Oncology Institute common stock in an open-market transaction. The weighted average purchase price was about $3.11 per share, with trades executed between $3.04 and $3.15 per share.

How many TOI shares does Jorey Chernett own after this transaction?

After the reported purchase, Jorey Chernett directly owns 10,401,929 shares of Oncology Institute common stock. This figure reflects the updated holding shown in the Form 4, following the acquisition of 125,000 additional shares in the open market.

At what prices were the TOI shares purchased by Jorey Chernett?

The 125,000 Oncology Institute shares were bought in multiple trades at prices ranging from $3.04 to $3.15 per share. The Form 4 discloses a weighted average purchase price of approximately $3.11 per share for the entire transaction.

What type of transaction did Jorey Chernett execute in TOI stock?

The filing describes an open-market purchase of common stock by Jorey Chernett. The transaction code is “P,” indicating a purchase in the open market or private transaction, and it involved 125,000 TOI shares at a weighted average price of about $3.11 per share.

Is Jorey Chernett considered a major shareholder of Oncology Institute (TOI)?

Yes. The Form 4 identifies Jorey Chernett as a ten percent owner of Oncology Institute. After buying 125,000 additional shares, Chernett’s direct holdings increased to 10,401,929 common shares, underscoring status as a significant shareholder in the company.